Can a new drug tame VEXAS syndrome and cut steroid dependence?

NCT ID NCT07748624

Not yet recruiting Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether an investigational drug called arumakimig can improve symptoms of VEXAS syndrome, a rare genetic autoinflammatory condition. The study will compare arumakimig against a placebo in about 120 adults with VEXAS, with the goal of seeing if the drug can reduce disease activity and allow patients to lower their steroid use. After the initial 52-week period, participants may continue into an open-label extension to assess long-term safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Arumakimig (MAS825), an investigational drug, given as an injection
What this could lead to: If successful, arumakimig could offer a new treatment option for VEXAS syndrome, potentially reducing symptoms and the need for steroids.
What could go wrong: This is an early-phase trial, so the drug may not work as hoped or may cause side effects. Results from this study will not be conclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VEXAS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arthralgia arthritic joint disease VEXAS syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VEXAS SYNDROME

More trials for these conditions

Other studies related to the condition(s) this trial covers.